Xiangyin Wei
Overview
Explore the profile of Xiangyin Wei including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
88
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hochhaus G, Chen M, Kurumaddali A, Schilling U, Jiao Y, Drescher S, et al.
AAPS J
. 2021 Nov;
24(1):1.
PMID: 34811595
No abstract available.
2.
Hochhaus G, Chen M, Kurumaddali A, Schilling U, Jiao Y, Drescher S, et al.
AAPS J
. 2021 Mar;
23(3):48.
PMID: 33768368
In the context of streamlining generic approval, this study assessed whether pharmacokinetics (PK) could elucidate the pulmonary fate of orally inhaled drug products (OIDPs). Three fluticasone propionate (FP) dry powder...
3.
Dutta R, Spence B, Wei X, Dhapare S, Hindle M, Longest P
Pharm Res
. 2020 Sep;
37(10):199.
PMID: 32968848
Purpose: The objective of this study was to optimize nose-to-lung aerosol delivery in an adult upper airway model using computational fluid dynamics (CFD) simulations in order to guide subsequent human...
4.
Caldas L, Matulewicz A, Koenig R, Wei X, Hindle M, Donohoe K
Curr Pharm Teach Learn
. 2020 Apr;
12(3):320-325.
PMID: 32273070
Background And Purpose: Combining pharmaceutics and pharmacy practice into nonsterile compounding is ideal to increase problem-solving skills. The objectives of this activity were to: (1) create a nonsterile compounding activity...
5.
Hosseini S, Wei X, Wilkins Jr J, Fergusson C, Mohammadi R, Vorona G, et al.
J Aerosol Med Pulm Drug Deliv
. 2019 Aug;
32(6):374-385.
PMID: 31464547
The majority of current nasal delivery devices, commercialized for children, are developed for adults. Differences in the dose reaching the target are expected due to significant differences between the pediatric...
6.
Spence B, Longest W, Wei X, Dhapare S, Hindle M
J Aerosol Med Pulm Drug Deliv
. 2019 Mar;
32(4):224-241.
PMID: 30855199
Aerosol drug delivery to the lungs is known to be very inefficient during all forms of noninvasive ventilation, especially when the aerosol is administered simultaneously with high-flow nasal cannula (HFNC)...
7.
Wei X, Hindle M, Kaviratna A, Huynh B, Delvadia R, Sandell D, et al.
J Aerosol Med Pulm Drug Deliv
. 2018 Jun;
31(6):358-371.
PMID: 29878859
correlations (IVIVC) for lung deposition may be established by testing inhalers with realistic mouth-throat (MT) models and inhalation profiles (IP). This study was designed to compare the currently available MT...
8.
Bhagwat S, Schilling U, Chen M, Wei X, Delvadia R, Absar M, et al.
Pharm Res
. 2017 Aug;
34(12):2541-2556.
PMID: 28799097
Purpose: The ability of two semi-mechanistic simulation approaches to predict the systemic pharmacokinetics (PK) of inhaled corticosteroids (ICSs) delivered via dry powder inhalers (DPIs) was assessed for mometasone furoate, budesonide...
9.
Wei X, Hindle M, Delvadia R, Byron P
J Aerosol Med Pulm Drug Deliv
. 2017 Mar;
30(5):339-348.
PMID: 28332899
Background: The dose and aerodynamic particle size distribution (APSD) of drug aerosols' exiting models of the mouth and throat (MT) during a realistic inhalation profile (IP) may be estimated in...
10.
Delvadia R, Wei X, Longest P, Venitz J, Byron P
J Aerosol Med Pulm Drug Deliv
. 2015 Oct;
29(2):196-206.
PMID: 26447531
Background: The amount of drug aerosol from an inhaler that can pass through an in vitro model of the mouth and throat (MT) during a realistic breath or inhalation flow...